[go: up one dir, main page]

WO2006016574A1 - Agent anticancéreux utilisant l'arn interférence - Google Patents

Agent anticancéreux utilisant l'arn interférence Download PDF

Info

Publication number
WO2006016574A1
WO2006016574A1 PCT/JP2005/014566 JP2005014566W WO2006016574A1 WO 2006016574 A1 WO2006016574 A1 WO 2006016574A1 JP 2005014566 W JP2005014566 W JP 2005014566W WO 2006016574 A1 WO2006016574 A1 WO 2006016574A1
Authority
WO
WIPO (PCT)
Prior art keywords
hsp105
sirna
expression
cancer
rnai
Prior art date
Application number
PCT/JP2005/014566
Other languages
English (en)
Japanese (ja)
Inventor
Yasuharu Nishimura
Tetsuya Nakatsura
Seiji Hosaka
Original Assignee
Kumamoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kumamoto University filed Critical Kumamoto University
Priority to JP2006531647A priority Critical patent/JPWO2006016574A1/ja
Publication of WO2006016574A1 publication Critical patent/WO2006016574A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an antitumor agent using RNAi. More specifically, the present invention relates to an antitumor agent using a factor capable of suppressing the expression of HSP105 by RNAi.
  • RNAi functions are inhibited! /
  • a double-stranded RNA consisting of sense RNA and antisense RNA that is homologous to a specific region of a gene interferes with the homologous portion of the target gene transcript mRNA. It was first proposed in 1998 by an experiment using nematodes. Later in 2001, it was found that 21-23 base pair double stranded RNA can induce RNAi effect in mammalian cells without cytotoxicity.
  • RNA interference method is simple and inexpensive, has the advantage that gene function can be analyzed in a short time, and the gene sequence to be inhibited should have at least 19 bases. It is.
  • siRNA expression vectors have been developed, and delivery methods using viral vectors are also in the development stage for medical applications. As described above, the RNA interference method is used as a technique for specifically suppressing the synthesis of gene products, and its application to medicine has been reported, but there are few reports that it has actually been effective.
  • HSP105 is a heat shock protein belonging to the HSP105 / HSP110 family, and it is known that its expression is induced by various stresses such as heat shock and other drugs. Although its function has not yet been fully elucidated, it is thought to bind to various proteins and to be involved in the activity of protecting against degradation and suppressing function. In mouse embryos, it has been shown that expression is transiently increased during embryonic period (Hatayama. T. et al. Cell Struct. Funct. 22,517-525. (1997)) 0 rat neurons It has also been shown that overexpression of HSP105 suppresses apoptosis induced by various stresses (Hatayama. T Et al. Biochem. Biophys. Res. Commun.
  • the present inventors have identified the ability to identify HSP105 in the SEREX method using serum from patients with spleen cancer and colon cancer. This indicates that IgG antibodies against HSP105 exist in the serum of cancer patients! (Nakatsura. T. et al. Biochem. Biophys. Res. Commun. 281, 936-944. (2001)).
  • the present inventors have also found that HSP105 is overexpressed in various human tumors as well as spleen and colon cancers (Kai. M. et al. Oncol. Rep. 10.1777- 1782. (2003)). On the other hand, it was found that in normal human tissues, expression was highest in the testis and weak expression was observed in some organs such as the brain.
  • An object of the present invention is to provide a novel antitumor agent utilizing the RNAi phenomenon. More specifically, an object of the present invention is to suppress the expression of HSP105 using siRNA of HSP105, study the effect on tumor, and provide a novel antitumor agent.
  • the present inventors transformed the mouse NIH3T3 cells by introducing the HSP105 gene, the present inventors thought that HSP105 has an oncogene-like function, and the main one is to suppress apoptosis.
  • the present inventors succeeded in causing the cells to undergo apoptosis. The effect was more prominent in the cancer cells expressing wild-type p53, and the effect was increased when used in combination with the pile cancer agent adriamycin.
  • HSP105 siRNA is considered to be effective against cancers that express phenotypes, and in addition, this gene therapy also has a synergistic effect on cancers with mutant P53. I can expect.
  • an antitumor agent comprising a factor capable of suppressing the expression of HSP105 by RNAi.
  • an apoptosis inducer in cancer cells comprising a factor capable of suppressing the expression of HSP105 by RNAi.
  • the factor capable of suppressing the expression of HSP105 by RNAi is siRNA or shRNA.
  • the agent of the present invention is used in combination with an anticancer agent.
  • the agents of the present invention are used against cancer cells that express wild-type p53.
  • the siRNA is a double-stranded RNA consisting of an RNA having the base sequence set forth in SEQ ID NO: 1 and an RNA having the base sequence set forth in SEQ ID NO: 2.
  • the agent of the present invention is used for the treatment of colorectal cancer, knee cancer, esophageal cancer, breast cancer, malignant melanoma and the like that highly express HSP105.
  • RNA having the base sequence set forth in SEQ ID NO: 1 and RNA having the base sequence set forth in SEQ ID NO: 2.
  • a method for suppressing a tumor comprising administering a factor capable of suppressing the expression of HSP105 by RNAi to a mammal including a human.
  • a method for inducing apoptosis in cancer cells comprising administering a factor capable of suppressing the expression of HSP105 by RNAi to a mammal including a human.
  • a factor capable of suppressing the expression of HSP105 by RNAi for the production of an apoptosis inducer in cancer cells.
  • the present invention relates to an antitumor agent and an apoptosis-inducing agent in cancer cells (hereinafter, these may be collectively referred to as the drug of the present invention) containing a factor capable of suppressing the expression of HSP105 by RNAi.
  • a factor capable of suppressing the expression of HSP105 by RNAi include siRNA and shRNA as described below.
  • double-stranded RNA having a length of about 20 bases (for example, about 21 to 23 bases) or less, called siRNA can be used in the present invention.
  • siRNA can suppress gene expression by being expressed in cells, and can suppress expression of a target gene of the siRNA (in the present invention, HSP105 gene).
  • siRNA used in the present invention may be in any form as long as it can cause RNAi.
  • siRNA is an abbreviation for short interfering RNA, which is artificially chemically synthesized, biochemically synthesized, or synthesized in organisms, or about This is short double-stranded RNA of 10 base pairs or more, which is formed by decomposing double-stranded RNA of 40 bases or more in the body, and usually has a 5'-phosphate or 3'-OH structure. The 3 'end protrudes about 2 bases.
  • a specific protein binds to this siRNA, and RISC (RNA-induced-silencing-complex) is established. This complex recognizes and binds to mRNA having the same sequence as that of siRNA, and cleaves mRNA at the center of siRNA by RNaselll-like enzyme activity.
  • the siRNA sequence and the mRNA sequence to be cleaved as a target match 100%.
  • the cleavage activity by RNAi often remains partially, so it does not necessarily have to match 100%.
  • the region having homology between the nucleotide sequence of siRNA and the nucleotide sequence of HSP105 gene whose expression should be suppressed preferably does not include the translation initiation region of HSP105 gene. Since various transcription factors and translation factors are expected to bind to the translation initiation region, siRNA This is because it cannot be effectively bound to mRNA and the effect is expected to be reduced. Therefore, the homologous sequence is preferably 20 bases away from the translation start region of the HSP105 gene! /, More preferably 70 bases away from the translation start region of the HSP105 gene.
  • the sequence having homology may be, for example, a sequence near the 3 ′ end of the HSP105 gene.
  • siRNA can be used as a factor that causes RNAi, and a factor that generates siRNA (for example, dsRNA of about 40 bases or more) can be used as such a factor.
  • a factor that generates siRNA for example, at least about 70%, preferably 75% or more, more preferably 80% or more, more preferably 85% or more, even more preferably 90% or more, particularly preferably 95% or more of a part of the nucleic acid sequence of the HSP105 gene.
  • RNA containing a double-stranded portion or a variant thereof containing a sequence having a homology of at least%, most preferably 100% can be used.
  • sequence portion having homology is usually at least about 15 nucleotides or more, preferably at least about 19 nucleotides, more preferably at least about 20 nucleotides in length, and even more preferably at least about 21 nucleotides in length. .
  • siRNA examples include RNA having a 21-base base sequence corresponding to the 138th to 158th positions of HSP105 mRNA, specifically, SEQ ID NO: 1 Forces including, for example, RNA having the nucleotide sequence described and RNA having the nucleotide sequence set forth in SEQ ID NO: 2 are not limited thereto.
  • the base sequence of the HSP105 gene is known, and is described in, for example, NCBI, Nucleotide Sequence Data base accession No. AB003334.
  • a shRNA short hair pin RNA
  • a shRNA is a molecule of about 20 base pairs or more that has a double-stranded structure within the molecule and has a hairpin-like structure by including a partially palindromic base sequence with single-stranded RNA.
  • shRNAi can be digested in the same manner as siRNA. Can cause.
  • shRNA causes RNAi as well as siRNA, and can be used effectively in the present invention.
  • the shRNA preferably has a 3 'protruding end.
  • the length of the double-stranded part is not particularly limited, but is preferably about 10 nucleotides or more, more preferably about 20 nucleotides or more.
  • the 3 ′ protruding end is preferably DNA, more preferably DNA of at least 2 nucleotides, and further preferably DNA of 2 to 4 nucleotides.
  • siRNA or shRNA can be used as a factor capable of suppressing the expression of HSP105 by RNAi.
  • the advantages of siRNA are as follows: (1) Even if it is introduced into cells, RNA itself is not integrated into the chromosome of normal cells! /, so it is safer than treatment that causes mutations transmitted to offspring, And (2) short double-stranded RNA is relatively easy to chemically synthesize and is more stable when double-stranded.
  • shRNA when treatment is performed by suppressing gene expression for a long time, a vector that transcribes shRNA in a cell can be prepared and introduced into the cell.
  • the factor capable of suppressing the expression of HSP105 by RNAi used in the present invention may be artificially chemically synthesized, sense strand and antisense. It can also be prepared by synthesizing RNA in vitro with T7 RNA polymerase, which has a hairpin structure in which the DNA sequences of the strands are ligated in the opposite direction.
  • T7 RNA polymerase which has a hairpin structure in which the DNA sequences of the strands are ligated in the opposite direction.
  • antisense and sense RNAs can be synthesized from the truncated DNA using T7 RNA polymerase and T7 promoter. When these are annealed in vitro and then introduced into cells, RNAi is triggered and HSP1 05 expression is suppressed.
  • such RNA can be introduced into cells using, for example, the calcium phosphate method or various transfection reagents (eg, oligofectamine, Lipofectamine, lipofection, etc.).
  • an expression vector comprising a nucleic acid sequence encoding a factor (preferably siRNA or shRNA) capable of suppressing the expression of HSP105 by RNAi.
  • a cell containing the above-described expression vector is provided.
  • the cells of the present invention may transiently or stably express a factor that causes RNAi.
  • the expression vectors and cell types described above are not particularly limited, but are preferably used for treatment. It can be done.
  • the agent of the present invention can be widely used for tumor suppression. More specifically, tumor suppression includes prevention of tumor development, suppression of tumor growth, tumor regression, and suppression of tumor migration. Clinically, cancer and Z or tumor prevention and Z Or means to encompass all of the treatment.
  • the types of cancer for which the antitumor agent of the present invention can be used are not particularly limited, and include all of benign tumors and malignant tumors.
  • Specific examples of cancer include malignant melanoma, malignant lymphoma, digestive cancer, lung cancer, esophageal cancer, gastric cancer, colon cancer, rectal cancer, colon cancer, ureteral tumor, gallbladder cancer, bile duct cancer, biliary tract cancer, breast cancer, Liver cancer, spleen cancer, testicular tumor, maxillary cancer, tongue cancer, lip cancer, oral cancer, pharyngeal cancer, laryngeal cancer, ovarian cancer, uterine cancer, prostate cancer, thyroid cancer, brain tumor, force positive sarcoma, hemangioma, leukemia , Polycythemia vera, neuroblastoma, retinoblastoma, myeloma, cystoma, sarcoma, osteosarcoma, myoma, skin cancer
  • the agent of the present invention can be used in combination with other anticancer agents.
  • the agent of the present invention can be administered together with certain anticancer agents or separately before and after.
  • cancer cells that have been resistant to such an anticancer agent can be effectively treated or prevented.
  • Alkylating agents for example, cyclophosphamide, busulfan, thiotepa, dacarbazine, etc.
  • Antimetabolite eg, methotrexate, 6-mercaptopurine, fluorouracil (5 FU), etc.
  • DNA topoisomerase inhibitors for example, camptothecin, etoposide, etc.
  • Tubulin agonists (vinblastine, vincristine, etc.)
  • Anticancer antibiotics (adriamycin, daunorubicin, mitomycin C, bleomycin, etc.)
  • Hormonal agents tamoxifen, leuprorelin, etc.
  • Biologics asparaginase, interferon, etc.
  • the administration method of the drug of the present invention includes oral administration and parenteral administration (for example, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, mucosal administration, rectal administration, intravaginal administration, administration to the affected area. Topical administration, dermal administration, etc.) and direct administration to the affected area.
  • parenteral administration for example, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, mucosal administration, rectal administration, intravaginal administration, administration to the affected area.
  • Topical administration, dermal administration, etc. direct administration to the affected area.
  • a pharmaceutically acceptable additive can be blended as necessary.
  • pharmaceutically acceptable additives include antioxidants, preservatives, colorants, flavors, and diluents, emulsifiers, suspending agents, solvents, fillers, bulking agents, buffering agents, Powers including, but not limited to, delivery vehicles, diluents, carriers, excipients and / or pharmaceutical adjuvants.
  • the dosage form of the drug of the present invention is not particularly limited! Examples of sputum include liquids, injections, sustained-release agents and the like.
  • the solvent used for formulating the drug of the present invention as the above-mentioned preparation may be either aqueous or non-aqueous.
  • Injections can be prepared by methods well known in the art. For example, after being dissolved in a suitable solvent (saline, buffer solution such as PBS, sterilized water, etc.), sterilized by filtration with a filter or the like, and then filled into a sterile container (for example, an ampule). Can be prepared. This injection may contain a conventional pharmaceutical carrier, if necessary. Administration methods using non-invasive catheters can also be used. Examples of the carrier that can be used in the present invention include neutral buffered physiological saline or physiological saline mixed with serum albumin.
  • the factor capable of suppressing the expression of HSP105 by RNAi which is an active ingredient of the drug of the present invention, can be administered in the form of a non-viral vector or a viral vector.
  • Such administration forms are known in the art, for example, a separate volume of experimental medicine “Basic technology of gene therapy” Yodosha, 1996; a separate volume of experimental medicine “Gene transfer & expression analysis experiment method” Yodosha, It is described in 1997.
  • a method of introducing a nucleic acid molecule using ribosome liposome method, HVJ-ribosome method, catonic ribosome method, lipofussion method, ribosome Effuction method, etc.
  • microinjection method and method of transferring nucleic acid molecules to cells together with carriers (metal particles) using a gene gun.
  • the originating expression vector for example, P CAGGS, pBJ- CMV, pcDNA3 . 1, pZeoSV (lnv itrogen Company or Stratagene Inc. force available), and the like.
  • lipofusion for example, lipofectamine 2000, oligofectamine
  • the HVJ-ribosome method encapsulates a nucleic acid molecule in a ribosome made of a lipid bilayer, and fuses the ribosome with an inactivated Sendai Winores (Hemagglutinating virus of Japan, HVJ). Include.
  • the HVJ-ribosome preparation method is described, for example, in a separate volume of experimental medicine “Basic Technology of Gene Therapy” Yodosha, 1996; a separate volume of experimental medicine “Gene Transfer & Expression Analysis Experiment Method” Yodosha, 1997.
  • RNAi HSP105 A gene can be introduced into a cell or tissue by introducing a DNA that expresses a factor capable of suppressing the expression of the gene and infecting the cell or tissue with the recombinant virus.
  • a factor capable of suppressing the expression of HSP105 by RNAi can be directly injected into a living organ or tissue.
  • the dosage of the drug of the present invention is a factor that can suppress the expression of HSP105 by the purpose of use, the severity of the disease, the patient's age, weight, sex, medical history, or RNAi as an active ingredient. It can be determined by those skilled in the art in consideration of the type of the above.
  • the dose of the factor capable of suppressing the expression of HSP105 by RNAi as an active ingredient is not particularly limited, and is, for example, about 0.1 ng to about 100 mgZkg, preferably about 1 ng to about 10 mg.
  • the frequency of administration of the drug of the present invention is, for example, once a day to once every several months (for example,
  • RNAi is generally effective for 1-3 days after administration. Therefore, it is preferable to administer daily to once every 3 days. When using an expression vector, it can be administered about once a week.
  • HSP105 mRNA expression was examined using reverse transcription-PCR (RT-PCR).
  • the human colon cancer cell line HCT116 was obtained from Dr. B. Vogelstein of Johns Hopkins University. Normal colon mucosa cDNA was purchased from Clontech.
  • RT-PCR was performed according to a known method.
  • a human HSP105 gene PCR primer that amplifies a 407 bp fragment was designed and used to perform an RT-PCR reaction consisting of 33 amplification cycles at 94 ° C, 5 minutes of initial denaturation, and an annealing temperature of 58 ° C. It was.
  • the HSP105 PCR primer sequence used was Sense: 5′-AGAGTAAAAGTCAAAGTG-3 ′ (SEQ ID NO: 5), Antisense: 5′-TTAGAAGGTCTTTCCCT-3 ′ (SEQ ID NO: 6).
  • the j8-actin PCR primer sequences for the control experiments are sense: 5′-CCTCGCCTTTGCCGATCC-3 ′ (SEQ ID NO: 7), antisense: 5′-GGATCTTC ATGAGGTAGTC AGTC-3 ′ (SEQ ID NO: 8).
  • HSP105 mRNA was strongly expressed in the HCT116 cell line compared to normal colon mucosa (Fig. 1).
  • siRNA small interference RNA
  • mRNA mRNA
  • HEP105 heat shock protein 105
  • Fig. 2 Luciferase siRNA was also purchased from Dharmacon. All were dissolved in an annealing buffer (100 mM KOAc, 30 mM HEPES-KOH pH 7.4, 2 mM MgOAc) to 20 ⁇ 20.
  • HSP105 siRNA sequence is sense: 5'-UUGGCUGCAACUCCGAUUGdTdT-3 '(SEQ ID NO: 1), and antisense: 5'-CAAUCGGAGUUGCAGCCAAdTdT-3' (SEQ ID NO: 2).
  • the Luciferase siRNA sequence is sense: 5'-CGUACGCGGAAUACUUCGAdTdT-3 '(SEQ ID NO: 3), antisense: 5'-UCGAAGUAUUCCGCGUACGdTdT-3' (SEQ ID NO: 4).
  • HCT116 strain with wild type p53
  • HCT116 wild type p53 deficient strain
  • FCS DMEM medium After 4 hours, add 2 ml of 10% FCS DMEM medium.After 24 and 48 hours, collect cells by trypsin treatment.A part of the cells for flowcytometry and the rest for Western blotting are lysis buffer (20 mM Tris-HC1 pH7 .4, 10% glycerol, 1% NP-40 [Roche], 200 mM NaCl, ImM Na VO, Protease inhibitor cocktail tablet 1 tablet (Roche))
  • a cell lysate was prepared.
  • HCT116 wild type p53-bearing strain
  • HCT116 wild type p53 deficient
  • HCT116 wild type p53-bearing strain
  • HCT116 wild type p53-deficient strain
  • HCT116 p53- /-Oligofectamine only 12.0% Luciferase- siRNA treatment
  • HSP105- siRNA treatment 18.1% HCT116 p53 + / + Oligofectamine only 11.2% Luciferase- siRNA treatment 9.6% HSP105- siRNA treatment 51.1%) ( Figures 4 and 5).
  • Example 2 12 hours after addition of siRNA, adriamycin was added to each well at a concentration of 200 ng / ml, and the effect was examined.
  • GFP siRNA was purchased from QIAGEN and used as a control siRNA.
  • the GFP siRNA sequence is sense: 5′-GCAAGCUGAC CCUGAAGUUCAU-3 ′ (SEQ ID NO: 9), antisense: 5′-GAACUUCAGGGUCAGCU UGCCG-3 ′ (SEQ ID NO: 10).
  • the human colon cancer cell line SW620 showed the most decreased expression of HSP105 protein after 24 hours, and apoptosis was strongly induced at this time. This is probably due to the rapid growth of SW620, and after 48 hours, cells with strong enough siRNAs proliferated, so this result was relatively obtained.
  • human liver cancer SK-Hepl the expression of HSP105 was suppressed most and apoptosis was strongly induced 48 hours later (Figs. 7 to 9).
  • siRNA HSP105 siRNA represented by SEQ ID NO: 1 and SEQ ID NO: 2 described in Example 2
  • siRNA 1 nmol + 20 ⁇ 1 oligofectamin + glucose water was synthesized with siRNA 1 nmol + 20 ⁇ 1 oligofectamin + glucose water to a final concentration of 5% grape solution 60 1. Following the volume of 4 tumors each with control siRNA.
  • V LXW 2 X 0.5
  • Figure 11 shows the measurement results. As shown in Fig. 11, HSP105-siRNA clearly inhibited tumor growth.
  • HSP105-siRNA suppressed the expression of HSP105 protein even in normal cells, but did not induce apoptosis. Furthermore, this protein expression suppression was also transient, and the strength recovered after about 10 days after the introduction of siRNA.
  • the antitumor agent of the present invention is expected to have a conventional antitumor effect by targeting a tumor-specific antigen using a new means.
  • the effect of the antitumor agent of the present invention was enhanced by the combined use with other anticancer agents.
  • the therapeutic effect is low in malignant tumors expressing wild-type P53, but the antitumor agent of the present invention is Expresses wild-type p53 It has been demonstrated to be more effective in cancer cell lines.
  • combined use with this gene therapy can be expected to have a synergistic effect on cancer with mutant p53.
  • the antitumor agent of the present invention can be used as a new malignant tumor therapeutic agent in the field of medical therapeutic agents.
  • FIG. 1 shows the results of examining the expression of HSP105 in normal human colon and human colon cancer cell line HCT116 by RT-PCR.
  • the expression of HSP105 mRNA was clearly higher in HCT116 than in normal colon.
  • FIG. 2 shows the siRNA sequence of human HSP105.
  • FIG. 3 shows the result of confirming the expression of HSP105 protein after siRNA treatment by Western blotting.
  • HSP105 expression was not decreased by treatment with the control luciferase siRNA.
  • FIG. 4 shows detection of apoptosis 48 hours after siRNA treatment of HCT116 cell line by ANNEXIN V staining using flowcytometry.
  • apoptosis was clearly induced by HSP1 05 siRNA treatment compared to treatment with Oligofectamine alone or luciferase siRNA, which was more prominent in HCT116 wild type.
  • FIG. 5 shows a graph of the results of FIG. 4 together with 24 hours later.
  • FIG. 6 shows detection of apoptosis 48 hours after siRNA treatment of HCT116 cell line by ANNEXIN V staining using flowcytometry (36 hours after addition of adriamycin 200 ng / ml). In combination with adriamycin, the cells could be more induced to apoptosis.
  • FIG. 7 shows the results of confirming protein expression of HSP105 by Western blotting after siRNA treatment of human colon cancer cell line SW620.
  • SW620 showed the lowest HSP105 expression 24 hours after siRNA treatment.
  • FIG. 8 shows detection of apoptosis by ANNEXIN V staining of SW 620 using flowcytometry after siRNA treatment of human colon cancer cell line SW620. Apoptosis is treated with siRNA 2
  • FIG. 9 shows the protein expression of HSP 105 by Western blotting 48 hours after siRNA treatment of SK-Hepl and the detection of apoptosis by ANNEXIN V staining. SK_Hep 1 had a marked decrease in HSP105 protein expression 48 hours after siRNA treatment, and apoptosis was induced.
  • FIG. 10 shows protein expression of HSP105 by Western blotting 48 hours after siRNA treatment and apoptosis detection by ANNEXIN V staining in human spleen cancer cell line PK8, gastric cancer cell line M- ⁇ , and MKN28 .
  • FIG. 11 shows the results of measuring the tumor volume over time after injecting HSP105 siRNA into the tumor on the back of the mouse. HSP105-siRNA suppressed tumor growth.
  • Fig. 12 shows the results of HSP105 protein expression by Western blotting after siRNA treatment of human normal fibroblast TURU and MORI, and flowcytometry after siRNA treatment of human normal fibroblast TURU and MORI. Shows detection of apoptosis by ANNEXIN V staining.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention révèle un nouvel agent anticancéreux utilisant le phénomène de l'ARN interférence. L'invention révèle spécifiquement un agent anticancéreux contenant un facteur qui est capable de supprimer l'expression du HSP105 à travers l'ARN interférence.
PCT/JP2005/014566 2004-08-12 2005-08-09 Agent anticancéreux utilisant l'arn interférence WO2006016574A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006531647A JPWO2006016574A1 (ja) 2004-08-12 2005-08-09 ＲＮＡｉを利用した抗腫瘍剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004235087 2004-08-12
JP2004-235087 2004-08-12

Publications (1)

Publication Number Publication Date
WO2006016574A1 true WO2006016574A1 (fr) 2006-02-16

Family

ID=35839343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/014566 WO2006016574A1 (fr) 2004-08-12 2005-08-09 Agent anticancéreux utilisant l'arn interférence

Country Status (2)

Country Link
JP (1) JPWO2006016574A1 (fr)
WO (1) WO2006016574A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381208B2 (en) 2006-08-08 2016-07-05 Rheinische Friedrich-Wilhelms-Universität Structure and use of 5′ phosphate oligonucleotides
US9399658B2 (en) 2011-03-28 2016-07-26 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US10059943B2 (en) 2012-09-27 2018-08-28 Rheinische Friedrich-Wilhelms-Universität Bonn RIG-I ligands and methods for producing them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISHIHARA K. ET AL: "Molecular cloning, expression and localization of human 105 kDa heat shock protein, hsp105", BIOCHIM.BIOPHYS.ACTA., vol. 1444, no. 1, 1999, pages 138 - 142, XP001024442 *
NISHIMURA Y.: "Hito T-saibo ga Ninshiki suru Shuyo Tokui Kogen no Dotei", HEISEI 15 NENDO GAN KENKYU NI KAKAWARU TOKUTEI RYOIKI KENKYU (GAN TOKUTEI) KENKYU HOKOKUSHO SHU ROKU, HEISEI 16 NEN, MARCH, pages 348 - 351, XP002999841 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9381208B2 (en) 2006-08-08 2016-07-05 Rheinische Friedrich-Wilhelms-Universität Structure and use of 5′ phosphate oligonucleotides
US10238682B2 (en) 2006-08-08 2019-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5′ phosphate oligonucleotides
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US10036021B2 (en) 2008-05-21 2018-07-31 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US10196638B2 (en) 2008-05-21 2019-02-05 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US9399658B2 (en) 2011-03-28 2016-07-26 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9896689B2 (en) 2011-03-28 2018-02-20 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US10059943B2 (en) 2012-09-27 2018-08-28 Rheinische Friedrich-Wilhelms-Universität Bonn RIG-I ligands and methods for producing them
US10072262B2 (en) 2012-09-27 2018-09-11 Rheinische Friedrich-Wilhelms-Universität Bonn RIG-I ligands and methods for producing them
US11142763B2 (en) 2012-09-27 2021-10-12 Rheinische Friedrich-Wilhelms-Universität Bonn RIG-I ligands and methods for producing them

Also Published As

Publication number Publication date
JPWO2006016574A1 (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
JP6023709B2 (ja) アポトーシス誘導剤
WO2010006239A2 (fr) Régulation d'apoptose par variants d'épissure spécifique neurale d'ig20
US20160175339A1 (en) Methods for detecting and modulating the sensitivity of tumor cells to anti-mitotic agents and for modulating tumorigenicity
Zhai et al. MicroRNA‐98 attenuates cardiac ischemia‐reperfusion injury through inhibiting DAPK1 expression
Matters et al. Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression
US20130237584A1 (en) CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
WO2012023345A1 (fr) Procédé et composition pour le traitement, la prévention et le diagnostic d'un cancer contenant des cellules souches cancéreuses ou issu de celles-ci
Wang et al. shRNA-mediated silencing of Y-box binding protein-1 (YB-1) suppresses growth of neuroblastoma cell SH-SY5Y in vitro and in vivo
JP4467559B2 (ja) 細胞増殖を阻害する組成物および方法
JP7664233B2 (ja) 治療
US20210054382A1 (en) Methods and compositions for diagnosing and treating prostate cancer based on long noncoding rna overlapping the lck gene that regulates prostate cancer cell growth
JP6768979B2 (ja) Ｈｓｐ４７の阻害物質を用いた、がん転移抑制
WO2006016574A1 (fr) Agent anticancéreux utilisant l'arn interférence
CN102459326A (zh) 新的gpcr蛋白及其用途
KR101913693B1 (ko) SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2006106599A1 (ja) 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び／又は治療のための医薬
US12286629B2 (en) Compositions and methods for treating endometriosis
JP2008525005A (ja) 新規の物質、および、それらの使用
KR20110084650A (ko) Ｈｐｖ 감염과 관련된 암의 치료용 조성물
Fang et al. Growth inhibition of a tongue squamous cell carcinoma cell line (Tca8113) in vitro and in vivo via siRNA-mediated down-regulation of skp2
JP2011093896A (ja) 癌治療剤
US20110224279A1 (en) Anticancer agent
JP2016088884A (ja) 腫瘍治療用組成物
US20130190240A1 (en) Tumor growth controlling method targeting galactosylceramide expression factor-1
WO2021016061A2 (fr) Inhibiteurs de microarn 451a pour le traitement de l'endométriose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006531647

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase